How Pfizer Achieved 'Switch Success' With Viagra and Nexium
Executive Summary
Pfizer secured two of the biggest prescription-to-OTC switches in recent years with the reclassification of Viagra and Nexium. Michelle Riddalls, Pfizer's director of regulatory affairs in Europe, offers her advice to firms looking to emulate this 'switch success'.
You may also be interested in...
Understanding The Post-COVID Health Consumer
HBW Insight speaks to industry expert Paul Wardle - who worked on Pfizer's Viagra switch - about how data analytics can help firms extract the “beacons of insight” to create the consumer health brands of tomorrow.
Association Updates: Cranz Returns To Lead BAH, Plus News From WSMI, PAGB And ASMI
Former AESGP head Dr Hubertus Cranz steps in to lead BAH; WSMI calls on WHO to back self-care; PAGB appoints Riddalls to regulatory role; and ASMI changes its name.
AESGP Conference Round-Up: Digital Disruption, Med Device Worries And The Benefits Of Switching
Speakers from the EMA and European Commission, as well as Pfizer and HRA Pharma, debated at the AESGP's Regulatory Conference the ongoing digital transformation of the European consumer healthcare market, the latest developments in the implementation of the new medical devices regulations, and the best ways to encourage Rx-to-OTC switching across the EU.